



44

FORM PTO-1449(Modified)	APPY. DOCKET NO. A0752/7001	SERIAL NO. 09/464,303
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Gregory L Stahl and Charles D. Collard	
	FILING DATE December 15, 1999	GROUP 1640 1644

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

NO	A	Sato et al., Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein. International Immunology. April 1994, Vol. 6, No. 4, Pages: 665-669.
NO	B	Endo et al., Exon structure of the gene encoding the humanmannose-binding protein-associated serine protease light chain: comparison with complement C1r and C1s genes. International Immunology. Sept. 1996, Vol. 8, No. 9, Pages 1355-1358.
NO	C	Thiel, et al., A second serine protease associated with mannan-binding lectin that activates complement. Nature. April 1997, Vol. 386, Pages. 506-510.
NO	D	Endo et al., Two lineages of mannose-binding lectin-associated serine protease (MASP) in vertebrates, J. Immunology. November 1998, Vol. 161, Pages 4924-4930.
NO	E	International Search Report - Intl. Appl. No., PCT/US99/29919 - December 15, 1999

EXAMINER <i>My De Cloupe</i>	DATE CONSIDERED 7-20-01
---------------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

#5

FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: A0752/7001(HCL)	SERIAL NO.: 09/464,303
	APPLICANT: Stahl et al.	
	FILING DATE: December 15, 1999	GROUP: 1646 1644

RECEIVED
NOV 21 1999
PATENT CENTER

U.S. PATENT DOCUMENTS							
Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

FOREIGN PATENT DOCUMENTS							
		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Publication, Etc.)		
AD	C1	Amsterdam, E.A. et al., "Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs", <i>Am J Physiol Heart Circ Physiol</i> , 1995, 268:H448-H457
AD	C2	Endo, Y. et al., "Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy," <i>Nephrol Dial Transplant</i> , August 1998, 13(8):1984-1990
AD	C3	Jack, D.L. et al., "Activation of complement by mannose-binding lectin on isogenic mutants of <i>Neisseria meningitidis</i> serogroup B, <i>J. Immunol</i> , February 1998, 160(3):1346-53 ABSTRACT ONLY
AD	C4	Vorup-Jensen, T. et al., "MASP-2, the C3 Convertase Generating Protease of the MBLectin Complement Activating Pathway", <i>Immunobiol.</i> , Vol. 199, 1998, Pages 348-357
AD	C5	Konami, Y. et al., "Correlation between carbohydrate-binding specificity and amino acid sequence of carbohydrate-binding regions of <i>Cytisus</i> -type anti-H(O) lectins", <i>FEBS Letters</i> , Vol. 304, No. 2.3, pages 129-135, June 1992
AD	C6	Lennon, P.F. et al., "Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences", <i>Am J Physiol Heart Circ Physiol</i> , 1996, 270:H1924-H1932
AD	C7	Linder, E. et al., "Activation of complement by cytoskeletal intermediate filaments", <i>Nature</i> , Vol. 278, 8 March 1979, pages 176-178
AD	C8	Linder, E., "Antibody-independent Binding of C1q and Activation of Serum Complement by Human Skin <i>in Vitro</i> " <The Journal of Investigative Dermatology, Vol. 78, No. 2, 1982, Pages 116-150
AD	C9	Linder, E. et al., "Activation of Complement by Intermediate Filaments of Glomerular Epithelial Cells", <i>Clinical Immunology and Immunopathology</i> , Vol. 40, 1986, Pages 265-275
AD	C10	Shikhman, A.R. et al., "Cytokeratin Peptide SFGSGFGGGY Mimics N-Acetyl-β-D-Glucosamine in Reaction with Antibodies and Lectins, and Induces <i>In Vivo</i> and Anti-Carbohydrate Antibody Response", <i>The Journal of Immunology</i> , 1994, Pages 5593-5606
AD	C11	Super, M. et al., "The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations", <i>Clin Exp Immunol.</i> , 1990, Vol. 79, Pages 144-150
AD	C12	Terai, I. et al., "Human serum mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1): determination of levels in body fluids and identification of two forms in serum", <i>Clin Exp Immunol</i> , 1997, Vol. 110, Pages 317-323
AD	C13	Turner, M.W., "The lectin pathway of complement activation", <i>Res Immunol</i> , February 1996, 147(2):110-5
AD	C14	Vakeva, A.P. et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion. Role of the Terminal Complement Components and Inhibition by Anti-C5 Therapy", <i>Circulation</i> , Vol. 97, June 9, 1998, Pages 2259-2267

EXAMINER <i>Ang De Chen</i>	DATE CONSIDERED 7-20-01
--------------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE STATEMENT

APR 12 2001

APR 16 2001

Sheet 1 of 2

APPLICATION NO.: 09/464,303

FILING DATE: December 15, 1999

APPLICANT: Gregory L. Stahl et al.

GROUP ART UNIT: 1646 1644

ATTY. DOCKET NO.:

EXAMINER: Unassigned

TECH CENTER 1600/2900 U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
Bo	B1	WO	99/39209	A1	Biogenese GmbH (Abstract Only in English)	08/05/1999	N
Bo	B2	WO	00/35483	A1	Brigham & Women's Hospital, Inc.	06/22/2000	
Bo	B3	WO	01/12212	A1	ISR Brigham & Women's Hospital, Inc.	02/22/2001	
	B4	WO	01/12212	A1	Brigham & Women's Hospital, Inc.	02/22/2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C15	AGAH, A. et al., "Isolation, Characterization, and Cloning of Porcine Complement Component C7", The Journal of Immunology, 2000, Pages 1059-1065, The American Association of Immunologists	
Bo	C16	COLLARD, C.D. et al., "Reoxygenation of hypoxic human umbilical vein endothelial cells (HUVECs) activates the lectin complement pathway (LCP)", <i>FASEB Journal</i> , March 17, 1998, Page 29A Abstract, Vol. 12, No. 4, Meeting Info: Annual Meeting of Professional Research Scientists on Experimental Biology 98, Part 1, San Francisco, CA, USA, April 18-22, 1998, Federation of American Societies of EX	
Bo	C17	COLLARD, C.D. et al., "Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells", <i>AJP-Cell Physiology</i> , February 1999, Pages C450-C458, Vol. 276, Issue 2	
Bo	C18	COLLARD, C.D. et al., "Endothelial reoxygenation activates the lectin complement pathway: Inhibition with anti-human mannose binding lectin (MBL) therapy", <i>Molecular Immunology</i> , March-April 1999, Page 278 Abstract, Vol. 36, No. 4-5, Meeting Info: 7 th European Meeting on Complement in Human Disease, Helsinki, Finland, June 17-20, 1999	
Bo	C19	COLLARD, C.D. et al., "Complement activation following oxidative stress", <i>Molecular Immunology</i> , 1999, Pages 941-948, Vol. 36, Elsevier Science Ltd.	
	C20	COLLARD, C.D. et al., "Complement Activation after Oxydative Stress, Role of the Lectin Complement Pathway", <i>American Journal of Pathology</i> , May 2000, Pages 1549-1556, Vol. 156, No. 5, American Society of Investigative Pathology	
Bo	C21	COLLARD, C.D. et al., "Endothelial oxidative stress increases cytokeratin 1 (K1) expression and human mannose-binding (MBL) deposition", <i>Immunopharmacology</i> , August 2000, Page 85 Abstract, Vol. 49, No. 1-2, Print Meeting Info: XVIII th International Complement Workshop, Salt Lake City, Utah, USA, July 23-27, 2000	
Bo	C22	FITCH, J.C.K. et al., "Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass", <i>Circulation</i> , December 21/28, 1999, Pages 2499-2506, American Heart Association	
Bo	C23	LHOTTA, K. et al., "Glomerular deposition of mannose-binding lectin in human glomerulonephritis", <i>Nephrology Dialysis Transplantation</i> , 1999, Pages 881-886, Vol. 14, European Renal Association, European Dialysis and Transplant Association	
Bo	C24	LINDER, E., "Binding of C1q and Complement Activation by Vascular Endothelium", <i>The Journal of Immunology</i> , February 1981, Pages 648-658, Vol. 126, No. 2	

AP	C25	TURNER, M.W., "Mannose-binding lectin: the pluripotent molecule of the innate immune system", <i>Review Immunology Today</i> , November 1996, Pages 532-540, Vol. 17, No. 11		

EXAMINER <i>Am D. Clune</i>	DATE CONSIDERED <i>7-20-07</i>
--------------------------------	-----------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

